期刊
HIV CLINICAL TRIALS
卷 14, 期 2, 页码 75-79出版社
TAYLOR & FRANCIS LTD
DOI: 10.1310/hct1402-75
关键词
anal infection; anal intraepithelial neoplasia; HIV-1 infection; human papillomavirus; male
资金
- Merck
- Qiagen
- Weill-Cornell Clinical and Translational Science Center (CTSC)) [K23 AI 55038, UL1 RR024996]
- UCLA CTSC [U01 CAl21947-01, M01 RR00865]
- UCSF Clinical and Translational Science Institute [UL1 RR024131]
Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P = .01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据